5 Key Takeaways

• 1

  The PULSAR extension trial evaluated the efficacy and safety of 8 mg aflibercept in patients with treatment-naive neovascular AMD.

• 2

  Patients switched from 2 mg to 8 mg maintained vision and extended treatment intervals without significant safety concerns.

• 3

  Eighty percent of patients in the extension trial could extend treatment intervals to 12 weeks or longer without vision loss.

• 4

  The study found no new safety signals, including glaucoma or retinal occlusive events, over the three-year period.

• 5

  The findings support offering 8 mg aflibercept to treatment-naive patients and those currently on 2 mg for better outcomes.